Sunflower Therapeutics Announces an Exclusive Sales Representation Agreement with Optimal Biotech Group
Article content
Article content
MEDFORD, Mass. — Sunflower Therapeutics (Sunflower), a public benefit corporation transforming global access to protein manufacturing capacity for diverse applications, announced today its exclusive sales representation agreement with Optimal Biotech Group, an authorized manufacturer's sales representative serving the biotechnology and pharmaceutical market for Northern California and the Pacific Northwest, including British Columbia. Located in one of the largest biotech hubs in the world, Optimal Biotech Group is Sunflower's first commercial representative established in the United States and Canada, marking a significant step in the company's ongoing product commercialization.
Article content
'The commercial launch of the Daisy Petal™ marks an exciting milestone for Sunflower Therapeutics,' said Dave Bianchi, Director of Commercial Operations at Sunflower Therapeutics. 'We're proud to bring our innovative protein manufacturing solutions to the U.S. market and partner with Optimal Biotech Group as we extend the reach of our technologies and deliver new capabilities to biomanufacturers across the West Coast Region.'
Article content
Sunflower's innovative Daisy Petal™ perfusion fermentation system is a breakthrough technology that uses a single-use assembly designed specifically for intuitive installation and a simple user experience. The system's hardware and controls are engineered and optimized for in-vessel perfusion utilizing a disposable stirred tank reactor outfitted with a unique in-vessel perfusion device that enables greater volumetric productivity from the bench through scale-up manufacturing. With this approach, the system boasts space-time yield benefits five-to-ten times greater compared to traditional fed-batch methods for the production of diverse proteins.
Article content
'Optimal Biotech Group is thrilled to collaborate with Sunflower Therapeutics on their groundbreaking in-vessel perfusion technology, enabling continuous biomass feeding, fluid harvesting, and cell retention — all within a controlled, healthy bioreactor environment,' said Phil Charnas, VP Business Development, Optimal Biotech.
Article content
Sunflower's bioprocessing software suite, compliant with Good Manufacturing Practices (GMP), includes HelianthOS™, Nursery™, and Harvest™. These tools enable walkaway automation of fermentation processes, easy to develop recipes that require no coding and secure storage of process data generated by the Daisy Petal™ System. Together, these three elements provide a cohesive ecosystem that enables efficient and intuitive operations throughout an entire campaign.
Article content
Sunflower Therapeutics is a unique biotech with a mission to transform bioeconomies worldwide by creating accessible solutions for protein product development and commercial manufacturing. Using our core technologies – an efficient host, data-driven methods and Contract Research Organization (CRO) services for process development, and continuous biomanufacturing equipment – our team aims to democratize bioprocessing.
Article content
Optimal Biotech Group is a trusted sales channel partner for California and the Pacific Northwest. We specialize in process analytical technologies and single use solutions for upstream bioprocessing. Our goal is to provide seamless process measurement solutions that integrate smoothly with your R&D, pilot, and manufacturing operations, helping your business develop life-saving human biotherapeutics.
Article content
Article content
Article content
Article content
Contacts
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
TRUBAR INC. ANNOUNCES INITIAL LAUNCH OF TRUBAR™ KIDS LINE
Introduction of TRUBAR ™ Kids Line in Sprouts Farmers Market marks brand's entry into the kids snack bar market with the highest fiber and protein content among leading competitors in the category VANCOUVER, BC, Aug. 5, 2025 /CNW/ - TRUBAR Inc. (" TRUBAR" or the " Company") (TSX Venture: TRBR) (OTCQX: TRBRF), a better-for-you snacking company focused on delivering high-quality, plant-based protein products with exceptional taste and made with clean, recognizable ingredients, today announced the initial launch of TRUBAR ™ Kids Line, a clean ingredient kids snack bar with protein and fiber, in Sprouts Farmers Market. TRUBAR ™ Kids is completely free of peanuts and tree nuts, making it an allergy-friendly option perfect for lunchboxes, backpacks, after-school snacks and everything in between. After a successful early trial in 40 stores, the new line, is available starting this week chain-wide across 400 Sprouts Farmers Markets in 24 states, features three flavors: Iced Oatmeal Blast Bar, Pop Goes Confetti Bar and Fudge-tastic Brownie Bar. The introduction of TRUBAR ™ Kids sets a new standard in the category with the highest fiber and protein content among the leading kids snack bars. Each 5-bar box delivers standout nutrition: 8–9 grams of plant-based protein and 7–8 grams of fiber per bar, depending on the flavor — all under 140 calories. A 12-bar box will follow in mid-to-late September and will be available nationwide at Amazon, Hy-Vee and "The launch of TRUBAR ™ Kids marks a milestone in our strategy to expand the market presence and visibility of the TRUBAR ™ brand with innovative flavor varieties and pack sizes to broaden our appeal to health-conscious consumers of all ages," said Erica Groussman, Chief Executive Officer, TRUBAR Inc. "We're excited to introduce a delicious, school safe snack that parents can trust and on-the-go kids can enjoy." About TRUBAR Inc. TRUBAR Inc. is a better-for-you snacking company focused on delivering high-quality, plant-based protein products with exceptional taste and made with clean, recognizable ingredients. TRUBAR ™, the Company's signature product line, is distributed through national retailers, club stores, and e-commerce platforms across North America. The Company is focused on expanding TRUBAR ™ 's presence throughout North America and select international markets. For more information, visit: Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE Trubar Inc.
Cision Canada
6 hours ago
- Cision Canada
Quantifind Joins Forces with OpenSanctions to Deliver the Gold Standard in Sanctions Compliance
PALO ALTO, Calif., Aug. 5, 2025 /CNW/ -- As sanction regimes become more complex and scrutiny intensifies, institutions need more than a list; they need data with provenance and a performant AI engine to leverage it. Quantifind, the leading provider of AI-powered risk intelligence for financial crime detection and mitigation, today announced a strategic partnership with OpenSanctions, a globally recognized provider of quality-focused and fully transparent sanctions and watchlist data. The partnership integrates OpenSanctions' graph-based data into Quantifind's Graphyte™ platform, bringing unprecedented accuracy, data integrity, and auditability to compliance teams worldwide. "Sanctions compliance today demands data quality rigor, and the stakes could not be higher," said Adam Mulliken, Chief Product Officer of Quantifind. "Our partnership with OpenSanctions provides our customers access to comprehensive, quality-checked, and fully traceable data that complements our AI platform's ability to detect and contextualize risk with accuracy, speed, and scale. It's a game-changing combination for organizations ready to replace outdated matching rules and proprietary, hand-curated lists in their sanctions programs." "We believe compliance and transparency go hand in hand," said Friedrich Lindenberg, Founder of OpenSanctions. "By partnering with Quantifind, we're equipping global institutions with data they can fully trust—data that's accurate and traceable. Quantifind's leading analytical platform enables financial services firms to leverage our data, identifying and understanding risk early, and avoiding exposure to sanctions and other regulatory penalties. Together, we're setting a new standard in sanctions intelligence." Purpose-Built for Real-World Complexity OpenSanctions consolidates and deduplicates data from over 290 dataset collections worldwide into a unified model. Every data point is traceable to its source, and updates are propagated through fully automated pipelines. Quantifind's Graphyte platform integrates this data alongside its proprietary entity resolution, name science, and risk typologies—resulting in greater risk signal accuracy, faster screening, lower false positives, and fully explainable alerts Shared Values Both organizations are mission-driven. OpenSanctions is committed to democratizing access to high-quality sanctions and watchlist data, inviting a broader collective to join the fight against global corruption; Quantifind is building both the platform and the community that can bring focus to real signals of risk amongst a sea of noise. Their Convergence collective on Sanctions Evasion brings together private-public partners to work across sectors to identify better solutions to growing issues. Together, the two companies aim to transform global sanctions compliance with a modern solution—a scalable AI engine powered by authoritative, open data. Beyond the collaboration on sanctions compliance, the two organizations intend to leverage their combined expertise to continue to address emergent, complex issues such as sanctions evasion network mapping, the growing use and misuse of cryptocurrency to facilitate crime and corruption, and malign state influence, to name a few. The OpenSanctions data is now natively available within Quantifind's Graphyte platform for sanctions screening, monitoring, and investigations. Media Contacts Annalisa Camarillo EVP, Marketing Quantifind [email protected] Frederik Richter Managing Director, Commercial OpenSanctions [email protected] SOURCE Quantifind
Cision Canada
8 hours ago
- Cision Canada
Seegene Unveils CURECA™ and STAgora™ at ADLM 2025, Advancing the Next Stage of Diagnostics
Dr. , Chairman and CEO of Seegene, highlights progress toward fully automated and data-driven molecular testing Introduction of CURECA™, the first fully unattended PCR automation system, and STAgora™, a real-time global data analytics platform Technologies designed to scale automation, enhance data insights, and support the company's long-term vision of a world free from diseases SEOUL, South Korea, Aug. 5, 2025 /CNW/ -- Seegene Inc., a global leader in molecular diagnostics, unveiled two new technologies at ADLM 2025 in Chicago (July 29–31) designed to advance laboratory automation and data-driven infectious disease monitoring. The company introduced CURECA™, world's first fully unattended PCR automation system, and STAgora™, a real-time data analytics platform intended to support earlier detection and precision care. Chairman Highlights Next Step in Molecular Diagnostics "With CURECA™ and STAgora™, we are taking an important step toward the future of diagnostics," said Dr. Jong-Yoon Chun, Chairman and CEO of Seegene, during a press conference with U.S. and global media on July 30. "Our goal is to enable laboratories worldwide to automate complex testing workflows and use diagnostic data more effectively, ultimately helping advance global efforts toward a world free from diseases." Today, most molecular testing systems remain only partially automated, dependent on skilled personnel for repetitive manual steps and fixed workflows that limit efficiency and scalability. CURECA™ Breaks the Limits of Automation to Reshape Global Diagnostics CURECA™ is the first system in the diagnostics industry designed to fully automate every step of PCR testing, including the traditionally manual pre-treatment stage. Seegene notes that achieving true full automation in diagnostics requires three key conditions: operation without highly trained professionals, continuous 24-hour processing, and uninterrupted specimen input. CURECA™ is designed to meet all three. Its dedicated module, CURECA™ Prep, processes a wide range of specimen types such as urine, blood, sputum, and stool, addressing one of the most persistent barriers to automation. With the module handling diverse specimen pre-treatment, the full CURECA™ system completes the entire PCR workflow from sample loading through nucleic acid extraction, amplification, and result analysis without manual intervention. The system is engineered for continuous 24-hour operation, aiming to minimize human error, improve workflow efficiency, and allow laboratories to allocate skilled staff to higher-value activities. Full automation has long been a challenge in diagnostics due to specimen variability and the reliance on trained personnel for repetitive pre-processing tasks. CURECA™ is intended to help laboratories overcome these constraints by providing a scalable and adaptable system that can be configured to fit different lab sizes and workflows. CURECA™ Prep could also potentially extend to other testing fields, such as clinical chemistry and immunodiagnostics, as Seegene continues to explore broader automation solutions. STAgora™ Transforms Diagnostic Data into Real-Time Clinical Intelligence STAgora™ is Seegene's latest platform, designed to collect and analyze PCR testing data in real time, providing laboratories with broader context to inform diagnostic workflows. The platform includes more than 40 analytical tools, offering functions such as infection trend tracking, hospital-level positivity monitoring, and multi-pathogen co-infection pattern analysis. Rather than serving as a simple data repository, STAgora™ is built as an integrated platform intended to help laboratories derive meaningful, aggregated insights from testing data. Today, individual test results often provide limited information without broader reference points. STAgora™ is designed to address this by enabling hospitals to build their own statistical datasets and compare aggregated data across institutions, helping them detect infection patterns faster and support more informed decision-making. The data shared through the platform is de-identified and formatted according to each institution's requirements, supporting secure, real-time exchange at local, national, or global levels. Advancing Toward a World Free from All Diseases Dr. Chun reiterated Seegene's long-term vision of building "a world free from diseases" noting that the introduction of CURECA™ and STAgora™ completes the company's five core technology pillars. These include Seegene's proprietary PCR technology, the SGDDS (Seegene Digitalized Development System) for automated assay development, its global Technology-Sharing Initiative, and now the addition of fully automated PCR testing and real-time data analytics capabilities. Industry experts at ADLM 2025 expressed strong interest in Seegene's new technologies. Jamel Giuma, President and CEO of Miami based laboratory IT consulting firm JTG Consulting Group, said, "I've attended many ADLM conferences over the years, and CURECA™ is one of the most innovative solutions I have seen so far. I believe it has the potential to simplify laboratory workflows, reduce the burden on lab personnel, and greatly enhance overall operational efficiency." "With CURECA™ and STAgora™, we're addressing long-standing barriers in molecular diagnostics," Dr. Chun added. "Just as smartphones and electric vehicles transformed their industries, we believe these technologies will redefine what is possible in diagnostic testing, helping laboratories worldwide achieve true automation, unlock the value of diagnostic data, and ultimately contribute to building a world free from diseases." Disclaimer CURECA™ and STAgora™ demonstrated at ADLM 2025 are pre-commercial technologies under development, not commercially available, and are not currently cleared for clinical diagnostic use in any jurisdiction.
